New strategy targets the ‘mesh’ around tumors to stop glioblastoma
Researchers may have found a way to halt the spread of aggressive brain tumors by targeting the environment around the cancer cells. A new study…
News
Groups unite to raise gynecologic cancer awareness in September
September is Gynecologic Cancer Awareness Month, and advocacy organizations are hosting events, sharing information on social media, and raising funds to advance research.
New campaigns launch for Blood Cancer Awareness Month
This September, during Blood Cancer Awareness Month, major organizations are launching new campaigns to increase awareness and support for the three main types of…
Novocure files for FDA approval of TTFields for pancreatic cancer
Novocure has filed an application asking the U.S. Food and Drug Administration to approve its Tumor Treating Fields (TTFields) therapy for treating locally advanced…
Glioblastoma treatment combo shows promise in pilot study
A combination therapy for glioblastoma showed encouraging early results, with all five patients treated in a pilot study responding to it. Based on the data,…
Stenoparib wins FDA fast track status for advanced ovarian cancer
The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
New gene therapy for multiple myeloma enters clinical trial
The first patient has been dosed in a Phase 1 clinical trial that’s testing a gene therapy for people with recurring or treatment-resistant multiple…
Xspray seeking FDA approval for oral CML treatment XS003
Xspray Pharma has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for its oral therapy XS003 (nilotinib) for the…
Study provides insight into pancreatic cancer development
Glitches in a cellular process that are often seen in neurodegenerative diseases and dementia may also play a role in pancreatic cancer development, a…
Modeyso becomes 1st FDA-approved treatment for rare glioma
Jazz Pharmaceuticals said the U.S. Food and Drug Administration (FDA) granted accelerated approval to the weekly oral therapy dordaviprone, to be marketed under the brand…
